Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)

Virchows Arch. 2023 Mar;482(3):463-475. doi: 10.1007/s00428-022-03435-z. Epub 2022 Nov 8.

Abstract

The aim of this study is to envisage a streamlined pathological workup to rule out CUPs in patients presenting with MUOs. Sixty-four MUOs were classified using standard histopathology. Clinical data, immunocytochemical markers, and results of molecular analysis were recorded. MUOs were histologically subdivided in clear-cut carcinomas (40 adenocarcinomas, 11 squamous, and 3 neuroendocrine carcinomas) and unclear-carcinoma features (5 undifferentiated and 5 sarcomatoid tumors). Cytohistology of 7/40 adenocarcinomas suggested an early metastatic cancer per se. In 33/40 adenocarcinomas, CK7/CK20 expression pattern, gender, and metastasis sites influenced tissue-specific marker selection. In 23/40 adenocarcinomas, a "putative-immunophenotype" of tissue of origin addressed clinical-diagnostic examinations, identifying 9 early metastatic cancers. Cell lineage markers were used to confirm squamous and neuroendocrine differentiation. Pan-cytokeratins were used to confirm the epithelial nature of poorly differentiated tumors, followed by tissue and cell lineage markers, which identified one melanoma. In total, 47/64 MUOs (73.4%) were confirmed CUP. Molecular analysis, feasible in 37/47 CUPs (78.7%), had no diagnostic impact. Twenty CUP patients, mainly with squamous carcinomas and adenocarcinomas with putative-gynecologic-immunophenotypes, presented with only lymph node metastases and had longer median time to progression and overall survival (< 0.001), compared with patients with other metastatic patterns. We propose a simplified histology-driven workup which could efficiently rule out CUPs and identify early metastatic cancer.

Keywords: Cancer of unknown primary (CUP); Carcinoma; Immunohistochemistry; Malignancies of undefined primary origin (MUO); Tissue of origin.

MeSH terms

  • Adenocarcinoma* / metabolism
  • Biomarkers, Tumor / analysis
  • Carcinoma, Squamous Cell* / diagnosis
  • Female
  • Humans
  • Immunohistochemistry
  • Keratins / analysis
  • Neoplasms, Unknown Primary* / diagnosis
  • Neoplasms, Unknown Primary* / pathology

Substances

  • Keratins
  • Biomarkers, Tumor

Grants and funding